These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25989953)

  • 21. [The quality of life after chemotherapy in advanced non-small cell lung cancer patients].
    Słowik-Gabryelska A; Szczepanik A; Kalicka A
    Pol Merkur Lekarski; 1999 Jan; 6(31):18-22. PubMed ID: 10344148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
    Yanagitani N; Tsuchiya S; Kaira K; Sunaga N; Tsuchiya Y; Sato K; Watanabe S; Nomura S; Sakai S; Saito R; Mori M
    Am J Clin Oncol; 2007 Oct; 30(5):487-91. PubMed ID: 17921708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
    Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
    J Clin Oncol; 2004 Oct; 22(19):3852-9. PubMed ID: 15326195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer.
    Hotta K; Ueoka H; Kiura K; Tabata M; Tanimoto M
    Lung Cancer; 2004 Oct; 46(1):61-76. PubMed ID: 15364134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
    Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
    Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.
    Tong KM; Laskin J; Ho C
    Lung Cancer; 2015 Mar; 87(3):296-302. PubMed ID: 25601487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.
    Hirsh V
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S62-70. PubMed ID: 21885001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
    Somer RA; Sherman E; Langer CJ
    Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; Balducci L; Ciardiello F; Di Maio M; Felip E; Langer C; Lilenbaum RC; Perrone F; Senan S; de Marinis F
    Clin Lung Cancer; 2015 Sep; 16(5):325-33. PubMed ID: 25862554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.
    Buck PO; Saverno KR; Miller PJ; Arondekar B; Walker MS
    Clin Lung Cancer; 2015 Nov; 16(6):486-95. PubMed ID: 25681298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with first-line cisplatin-based chemotherapy: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Karakus A; Isikdogan A
    J BUON; 2012; 17(3):533-6. PubMed ID: 23033295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.
    Belani CP; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Fossella F;
    Lung Cancer; 2006 Aug; 53(2):231-9. PubMed ID: 16787687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of advanced non-small-cell lung cancer in special populations.
    Lilenbaum RC
    Oncology (Williston Park); 2004 Sep; 18(10):1321-5; discussion 1326, 1329-33. PubMed ID: 15526837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
    Sacher AG; Le LW; Lau A; Earle CC; Leighl NB
    Cancer; 2015 Aug; 121(15):2562-9. PubMed ID: 25891153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC).
    Gridelli C; Camerini A; Pappagallo G; Pennella A; Anzidei M; Bellomi M; Buosi R; Grasso RF
    Cancer Imaging; 2016 Dec; 16(1):44. PubMed ID: 28031049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.
    Laurie SA; Banerji S; Blais N; Brule S; Cheema PK; Cheung P; Daaboul N; Hao D; Hirsh V; Juergens R; Laskin J; Leighl N; MacRae R; Nicholas G; Roberge D; Rothenstein J; Stewart DJ; Tsao MS
    Curr Oncol; 2019 Feb; 26(1):e81-e93. PubMed ID: 30853813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chemotherapy in unfit bladder cancer patients].
    Goldwasser F; Mir O; Ropert S
    Bull Cancer; 2010; 97 Suppl Cancer de la vessie():35-41. PubMed ID: 20534388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC).
    Pentheroudakis G;
    Ann Oncol; 2020 Sep; 31(9):1265-1266. PubMed ID: 32502714
    [No Abstract]   [Full Text] [Related]  

  • 40. Changing health care costs for NSCLC, what does it mean?
    Postmus PE
    Lung Cancer; 2018 Mar; 117():62-63. PubMed ID: 29174372
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.